Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting1
Withdrawn1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06626269Not ApplicableRecruiting

Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies

NCT02470819Not ApplicableWithdrawn

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Showing all 2 trials

Research Network

Activity Timeline